UBS Group’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-18,233
| Closed | -$171K | – | 9118 |
|
|
2020
Q3 | $171K | Sell |
18,233
-9,415
| -34% | -$89.5K | ﹤0.01% | 4889 |
|
|
2020
Q2 | $212K | Buy |
27,648
+11,568
| +72% | +$88.5K | ﹤0.01% | 4768 |
|
|
2020
Q1 | $100K | Sell |
16,080
-11,062
| -41% | -$97.5K | ﹤0.01% | 5300 |
|
|
2019
Q4 | $331K | Buy |
27,142
+26,897
| +10,978% | +$294K | ﹤0.01% | 5206 |
|
|
2019
Q3 | $1.73M | Sell |
245
-78,425
| -100% | -$825K | ﹤0.01% | 3442 |
|
|
2019
Q2 | $786K | Buy |
78,670
+78,539
| +59,953% | +$847K | ﹤0.01% | 3940 |
|
|
2019
Q1 | $2K | Sell |
131
-97,125
| -100% | -$1.45M | ﹤0.01% | 7491 |
|
|
2018
Q4 | $1.48M | Buy |
97,256
+57,440
| +144% | +$1.09M | ﹤0.01% | 3327 |
|
|
2018
Q3 | $797K | Buy |
39,816
+38,025
| +2,123% | +$866K | ﹤0.01% | 4049 |
|
|
2018
Q2 | $35K | Sell |
1,791
-132,599
| -99% | -$2.93M | ﹤0.01% | 6289 |
|
|
2018
Q1 | $2.71M | Buy |
134,390
+86,611
| +181% | +$1.47M | ﹤0.01% | 2874 |
|
|
2017
Q4 | $633K | Buy |
47,779
+23,228
| +95% | +$350K | ﹤0.01% | 4117 |
|
|
2017
Q3 | $453K | Sell |
24,551
-34,542
| -58% | -$644K | ﹤0.01% | 4287 |
|
|
2017
Q2 | $1.09M | Buy |
59,093
+58,320
| +7,545% | +$1.16M | ﹤0.01% | 3546 |
|
|
2017
Q1 | $18K | Sell |
773
-40,326
| -98% | -$965K | ﹤0.01% | 6231 |
|
|
2016
Q4 | $1.43M | Buy |
41,099
+25,717
| +167% | +$768K | ﹤0.01% | 3227 |
|
|
2016
Q3 | $377K | Sell |
15,382
-32,518
| -68% | -$813K | ﹤0.01% | 4104 |
|
|
2016
Q2 | $1.15M | Buy |
47,900
+45,859
| +2,247% | +$1.05M | ﹤0.01% | 3266 |
|
|
2016
Q1 | $48K | Sell |
2,041
-811
| -28% | -$19.2K | ﹤0.01% | 5544 |
|
|
2015
Q4 | $86K | Sell |
2,852
-55,891
| -95% | -$1.81M | ﹤0.01% | 5339 |
|
|
2015
Q3 | $2.33M | Buy |
58,743
+22,420
| +62% | +$1.39M | ﹤0.01% | 2599 |
|
|
2015
Q2 | $2.51M | Buy |
36,323
+3,568
| +11% | +$224K | ﹤0.01% | 2758 |
|
|
2015
Q1 | $1.79M | Buy |
32,755
+11,406
| +53% | +$544K | ﹤0.01% | 3035 |
|
|
2014
Q4 | $910K | Buy |
+21,349
| New | +$771K | ﹤0.01% | 3648 |
|
UBS Group's AMAG Position: Q4 2020 in Review
UBS Group sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 18,233 shares — an estimated $171K sold.
UBS Group first reported a position in AMAG in Q4 2014 and held it in 24 quarters. The position peaked at $2.71M in Q1 2018. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- UBS Group reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- UBS Group sold 18,233 AMAG Pharmaceuticals shares in Q4 2020, an estimated $171K.
- UBS Group first reported a position in AMAG Pharmaceuticals in Q4 2014 and held it in 24 quarters.
- UBS Group's AMAG Pharmaceuticals position peaked at $2.71M in Q1 2018.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on UBS Group's 13F filing for Q4 2020, filed 11 Feb 2021.